Company intelligence / Profile preview
TQ Therapeutics GmbH
- Ownership
- Private
- Development stage
- Preclinical
Overview
TQ Therapeutics is developing an ultra-fast, automated extracorporeal gene therapy platform that brings cell therapy directly to patients instead of using conventional centralized production facilities.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Cell therapyGene therapyCAR-T cells
- Industry
- Biotech
Drug pipeline
5 assets4 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on TQ Therapeutics GmbH.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TQ Therapeutics GmbH.